申请人:Novo Nordiskals
公开号:US06001832A1
公开(公告)日:1999-12-14
The present invention relates to [1,2,4]triazolo[4,3-a]quinoxalinone compounds of the formula ##STR1## wherein R.sup.1 is POX'X" or alkyl substituted with COX' or POX'X", and X' and X" independently are hydroxy or alkoxy, and R.sup.7 is trifluoromethyl, and R.sup.6, R.sup.8 and R.sup.9 independently are piperidino, piperazinyl, morpholino, or thiomorpholino, which rings are optionally substituted with one or more of phenyl or C.sub.1-6 -alkyl and phenyl optionally being substituted with C.sub.1-6 -alkoxy; and pharmaceutically acceptable salts thereof. The compounds of the present invention are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters.
本发明涉及式为##STR1##的[1,2,4]三唑并[4,3-a]喹喔啉酮化合物,其中R.sup.1为POX'X"或烷基取代的COX'或POX'X",X'和X"独立地为羟基或烷氧基,R.sup.7为三氟甲基,R.sup.6、R.sup.8和R.sup.9独立地为哌啶基、哌嗪基、吗啉基或硫代吗啉基,这些环可选择地取代为一个或多个苯基或C.sub.1-6-烷基,苯基可选择地取代为C.sub.1-6-烷氧基;以及其药学上可接受的盐。本发明的化合物在治疗由兴奋性神经递质过度活跃引起的症状中是有用的。